Get started

Piramalpharma

PPLPHARMA: 8 Month Slopping Downwards Trendline BreakoutNSE:PPLPHARMA : This Pharma Stock Broke Out of Its Descending Triangle Prison Price Action: - Current Price: ₹216.22 (as of July 15, 2025) - 52-week Range: ₹181.73 - ₹307.90 - The stock has been in a clear descending triangle pattern since November 2024 - Price has been consistently making lower highs while finding support around the ₹190-200 zone - Recent price action shows signs of consolidation near the apex of the triangle Volume Spread Analysis: - Average daily volume: 4.68M shares - Volume spikes were observed during significant price movements in November 2024 and March 2025 - Recent volume has been relatively subdued, indicating a lack of conviction in either direction - Volume pattern suggests an accumulation phase with periodic distribution Key Technical Levels: Support Levels: - Primary Support: ₹190-200 (multiple tests, strong base) - Secondary Support: ₹181.73 (52-week low) - Psychological Support: ₹175-180 zone Resistance Levels: - Immediate Resistance: ₹230-240 (descending trendline) - Secondary Resistance: ₹250-260 (previous swing high) - Major Resistance: ₹280-290 (November 2024 high) Base Formation: - The stock has formed a solid base between ₹190-220 over the past 4 months - This base represents a potential accumulation zone for institutional investors - The horizontal support at ₹200 has been tested multiple times, showing its significance Technical Patterns: - Primary Pattern: Descending Triangle - Secondary Pattern: Potential Cup and Handle formation if the stock breaks above ₹240 - The descending triangle spans approximately 8 months, making it a significant pattern Trade Setup: Entry Strategy: - Breakout Entry: Buy above ₹240 with volume confirmation - Support Entry: Buy near ₹200-205 for swing trade - Conservative Entry: Wait for weekly close above ₹245 for momentum play Exit Levels: - Short-term Target: ₹260-270 - Medium-term Target: ₹290-300 - Long-term Target: ₹350-380 Stop-Loss Levels: - For breakout trades: ₹225 (below breakdown level) - For support trades: ₹185 (below 52-week low) - Trailing stop: 8-10% below entry price Position Sizing: - Risk per trade: Maximum 2% of portfolio - For ₹240 entry with ₹225 stop: Position size = (Portfolio × 0.02) / 15 - Suggested allocation: 1-2% of total portfolio for this trade Risk Management: - Maximum holding period: 3-6 months - Review position if stock fails to break ₹240 within 4 weeks - Partial profit booking at ₹270 (book 50% position) - Trail stop-loss after first target achievement Sectoral and Fundamental Backdrop: Sectoral Analysis: - The India Pharmaceutical Market size is estimated at USD 66.66 billion in 2025, and is expected to reach USD 88.86 billion by 2030, at a CAGR of 5.92% during the forecast period (2025-2030) - India's pharmaceutical industry ranks third globally in pharmaceutical production by volume and 14th by value, supported by a well-established domestic sector comprising approximately 3,000 drug companies and over 10,000 custom manufacturing units - The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024, as per ICRA - The biosimilars market in India is expected to grow at a CAGR of 22%, reaching USD 12 billion by 2025, representing nearly 20% of the country's pharmaceutical market Company Fundamentals: - Market Cap: 28,745 Crore (up 42.2% in 1 year), Revenue: 9,151 Cr, Profit: 91.1 Cr - Stock is trading at 3.53 times its book value - The company has a low interest coverage ratio, Promoter Holding: 34.94% - The P/E ratio of Piramal Pharma Ltd is 324 times as on 15-July-2025, a 651% premium to its peers' median range of 33.45 times Business Overview: - The company has a 49% ownership interest in a joint venture with Allergan India Pvt. Ltd (Avvyie, a US pharmaceutical company, holds a 51% ownership interest), which is one of the leading pharmaceutical companies in Ophthalmology formulations in India - Strong presence in glaucoma and dry eye treatments - Diversified portfolio across multiple therapeutic areas Analyst Targets: - Recent research reports show an average share price target of 253 - The estimated share price target for 2025 can range from ₹198 to ₹350 Investment Thesis: Bullish Factors: - Strong sectoral tailwinds with the Indian pharma market growing at 5.92% CAGR - Solid base formation indicating institutional accumulation - Reasonable valuation compared to growth prospects - Strategic partnership with Allergan provides a competitive advantage Risk Factors: - A high P/E ratio indicates expensive valuation - A low interest coverage ratio suggests financial stress - Regulatory changes in the pharmaceutical sector My Take: NSE:PPLPHARMA presents a mixed technical picture with a descending triangle pattern Breakout but strong support base. The stock is at a crucial juncture where a breakout above ₹240 could lead to significant upside, while a breakdown below ₹190 would confirm further weakness. Given the positive sectoral outlook and the company's strategic positioning, a breakout trade above ₹240 with proper risk management offers favorable risk-reward ratio. Keep in the Watchlist. NO RECO. For Buy/Sell. 📌Thank you for exploring my idea! I hope you found it valuable. 🙏FOLLOW for more 👍BOOST if you found it useful. ✍️COMMENT below with your views. Meanwhile, check out my other stock ideas on the right side until this trade is activated. I would love your feedback. Disclaimer: "I am not a SEBI REGISTERED RESEARCH ANALYST AND INVESTMENT ADVISER." This analysis is intended solely for informational and educational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.
NSE:PPLPHARMALong
by Karanshah137
19
Piramal Pharma Yet to Breakout? | MotherBar + CT + Supply DemandPiramal Pharma Ltd is at a critical juncture! 🚀 The stock is consolidating within a counter trendline (CTL) while respecting the rising trendline support. Key highlights: ✅ Mother Candle Formation - A large weekly candle acting as a range. ✅ Counter Trendline Breakout Watch - Price is still testing resistance, a breakout could trigger momentum. ✅ Demand Zone Support - The highlighted zone could act as a buying area. ✅ Volume Analysis - Increasing volumes hint at potential accumulation. Will this breakout or get rejected? Let’s watch price action carefully! 📊🔥
NSE:PPLPHARMALong
by Averoy_Apoorv_Analysis
Bullish Momentum for Piramal Pharma Above 235, Targeting 285+Details: Asset: Piramal Pharma Limited (PIRAMALPHARMA) Breakout Level: 235 Potential Target: 285+ with potential for further gains Stop Loss: Below 235 or as per risk tolerance Timeframe: Short to medium-term Rationale: Piramal Pharma has shown strong bullish momentum above the 235 level, and it is now targeting 285. The stock's technical indicators suggest continued strength, positioning it for a further upward move if it sustains this breakout. Market Analysis: Technical Setup: Breaking and sustaining above 235 suggests an ongoing bullish trend, with 285 as the immediate target. Bullish Indicators: Price action above 235 with significant buying volume implies a bullish sentiment that could drive the stock even higher. Price Target: The initial target is 285, with room for further gains if momentum continues. Risk Management: A stop loss below 235 is recommended to manage risk in case of reversal. Timeframe: The move towards 285+ is expected in the short to medium-term, subject to sustained buying pressure and market support. Risk-Reward Ratio: Favorable, with limited downside below 235 and strong upside potential, making it a bullish setup for near-term gains. Monitor market trends and volume to confirm sustained bullish momentum and consider the broader market sentiment as you track Piramal Pharma’s movement.
NSE:PPLPHARMALong
by CyborgTradingHub
1
Breakout From Tight Consolidation Range With VolumesNSE:PPLPHARMA today broke from the Narrow Consolidation Phase. After the previous Breakout in the consolidation phase, letting the 50 EMA Catch up, There Was continuous accumulation, as you can see from the volume intensity in the range. Today, on the back of magnificent Q2 FY 24-25 results, The Stock has blasted to a new All-Time High. View: Although the Stock is Overvalued at 588 P/E. Investors Should do Stock SIP or Buy on DIPS and Traders Should Wait for a Retracement to 50 EMA or a Good Consolidation Going Forward. NSE:PPLPHARMA is part of the Piramal group of companies. The company operates through 3 major segments. 1) Contract development and manufacturing organisations (CDMO) 2) Complex hospital generics (critical care) 3) Consumer Healthcare, Over-the-Counter (OTC) NSE:PPLPHARMA entered the Pharma space in 1988 with the acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions and various organic initiatives. In 2010 the Domestic formulations business was sold to About $3.7 billion and Diagnostic Services were sold to Super Religare Laboratories (SRL). 🙋‍♀️🙋‍♂️If you have any questions about this stock, feel free to reach out to me. 📌Thank you for exploring my idea! I hope you found it valuable. 🙏FLLOW for more 👍BOOST if useful ✍️COMMENT Below your views. Meanwhile, check out my other stock ideas below until this trade is activated. I would love your feedback. Disclaimer: This analysis is intended solely for informational and educational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.
NSE:PPLPHARMALong
by Karanshah137
PPLPHARMA STRONG BULLISH CANDLEPiramal Pharma Ltd Strong Bulish candle formation after QTR Result of company good QTR result and breakout found on chart good levels for entry after a pullback or INTRADAY continuation trade with strict Stop Loss **Disclaimer:** This information is for educational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Always do your own research and consult with a financial advisor before making investment decisions.
NSE:PPLPHARMALong
by rajatbhawra
1
PIRAMAL PHARMAPPL offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan (now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Little's, Tetmosol, i-Pill and Polycrol.
BSE:PPLPHARMALong
by CannySunny
PIRAMAL PHARMA (Looks Ready For 167, 195 Levels)PIRAMAL PHARMA is in uptrend since 60-61 level. The stock might achieve 167, 195 levels in the coming few months. Also, a good volume buildup can be seen on the weekly chart since last few session. The level of 142 can act as a support level. Disclaimer: I am not a SEBI registered analyst. All the stocks are for educational purposes. Investors must consult a financial advisor before making any investment. It is not a buy or sell recommendation.
NSE:PPLPHARMALong
by onkarsoundankar